Monitor upcoming topline data from the chronic pain Phase 1b trial expected in Q2 2026 and progress in the IPF Phase 2 trial. The increased ATM capacity provides funding flexibility but could lead to future dilution.
CTNM drugs
CTNM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 6 $13.88entry
- T+1 · 8mo ago −2.45%α −3.30% · $13.54
- T+5 · 8mo ago −6.34%α −4.81% · $13.00
- T+20 · 8mo ago −3.17%α −1.13% · $13.44
- T+60 · 6mo ago −5.69%α −18.47% · $13.09
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Contineum Therapeutics reported Q4 2025 financial results showing a net loss of $15.2 million and research and development expenses of $12.8 million. The company raised $93 million in a public offering and increased its at-the-market (ATM) equity offering capacity from $75 million to $100 million. They initiated patient dosing in a Phase 2 trial for IPF and expect topline data from a chronic pain trial in Q2 2026. With $262.9 million in cash, they project runway into mid-2029.
Key Financial Metrics
Key Facts
- Net loss of $15.2 million for Q4 2025, compared to $14.6 million in Q4 2024
- Cash, cash equivalents, and marketable securities totaled $262.9 million as of December 31, 2025
- Completed public offering generating $93 million in net proceeds
- Increased ATM equity offering capacity from $75 million to $100 million
- Initiated patient dosing in PROPEL-IPF Phase 2 trial for idiopathic pulmonary fibrosis
- Projected cash runway extends into mid-2029
Financial Impact
Cash increased to $262.9 million after $93 million public offering; R&D expenses decreased 2% to $12.8 million
Risk Factors
- Biotech stocks are inherently volatile with binary outcomes based on clinical trial results
- Increased ATM capacity could lead to significant share dilution if utilized
- Company remains in clinical stage with no approved products, dependent on successful trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-015159 |
| Document: ctnm-20260305.htm | 0001628280-26-015159 |
| Document: a2026_marchx8kxex-11.htm | 0001628280-26-015159 |
| Document: a2026_marchx8kxex-51.htm | 0001628280-26-015159 |
| Document: 0001628280-26-015159-index-headers.html | 0001628280-26-015159 |
| Document: 0001628280-26-015159-index.html | 0001628280-26-015159 |
| Document: 0001628280-26-015159.txt | 0001628280-26-015159 |
Track record
14 reports on CTNM
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $9.72 Now $9.67 −0.46% settles Dec 15
- Nov 10, 20266d ago Institutional Cluster Neutral 2/10 Entry $10.56 Now $9.67 −8.43% settles Dec 9
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $9.52 Now $9.67 +1.58% settles Dec 7
- Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $8.81 Now $9.67 +9.76% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $8.81 Now $9.67 +9.76% settles Dec 4
- Nov 3, 202613d ago 8-K Neutral 3/10 Entry $9.79 Now $9.67 −1.23% settles Dec 3
- Oct 28, 202619d ago SC 13G Neutral 3/10 Entry $9.33 Now $9.67 +3.64% settles Nov 27
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $9.15 Now $9.67 +5.68% settles Nov 25
- Oct 22, 202625d ago SC 13G Neutral 3/10 Entry $8.31 Now $9.67 +16.37% settles Nov 20
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $13.40 to $8.46 Now $9.67 −27.84% ▼ −36.87% −36.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers